TCR² re­leas­es ear­ly da­ta from some PhI pa­tients, spark­ing op­ti­mism from an­a­lysts

3 years ago
R&D

Covid-19 roundup: As­traZeneca builds $261M deal with US CD­MO play­er for bulk Covid-19 vac­cine sup­ply; Cor­po­rate in­sid­ers reel­ing in over $1B+

3 years ago
Coronavirus

As­traZeneca mines an­oth­er $6B ADC from Dai­ichi Sankyo, with block­buster am­bi­tions to ‘re­de­fine treat­ment stan­dards’

3 years ago
Deals

Bil­lion­aire Di­et­mar Hopp steers his se­cre­tive Covid-19 biotech play­er to Nas­daq fol­low­ing ma­jor pact with GSK

3 years ago
Financing

Gilead’s Kite snares a land­mark FDA OK on a $373,000 CAR-T ther­a­py — which comes with brag­ging rights to the first true fran­chise op

3 years ago
Cell/Gene Tx
FDA+

An­oth­er four biotechs make Wall Street de­but, rais­ing $772M+ as IPO tidal wave crests

3 years ago
Financing

Jeff Capel­lo out the door as Michael Mc­Don­nell takes over Bio­gen's CFO post; Ron Bruehlman named in­ter­im CFO at IQVIA

3 years ago
Peer Review

Could a patent rul­ing threat­en Mod­er­na’s Covid-19 vac­cine?

3 years ago
Pharma

Turn­ing can­cer in­to a cur­able dis­ease: Im­munother­a­py ex­pert John Con­nol­ly picks up the reins as the new CSO of Sean Park­er’s can­cer in­sti­tute

3 years ago
People
Peer Review

The phar­ma world's cham­pi­on patent wall builder is called out for their 'drip-feed' strat­e­gy to safe­guard the next megablock­buster fran­chise

3 years ago
Bioregnum
Pharma

Covid-19 roundup: UK adds $125M to build a new vac­cine man­u­fac­tur­ing cen­ter; Pfiz­er’s $2 bil­lion con­tract sets bench­mark vac­cine price — for bet­ter or worse

3 years ago
Coronavirus

The out­lier: 2020 may go down as one of the biggest eco­nom­ic melt­downs in US his­to­ry — but bio­phar­ma is boom­ing

3 years ago
Financing

Hous­ton’s huge R&D hub takes cen­ter stage in feds’ cam­paign to clip Chi­na’s ties to re­searchers, IP theft

3 years ago
China

Covid-19 roundup: Pfiz­er/BioN­Tech’s Warp Speed deal means big mon­ey for two bil­lion­aire twins; No­vavax lays out a rich smor­gas­bord of stock op­tions for ... Phase II?

3 years ago
Coronavirus

Jus­tice De­part­ment ac­cus­es Chi­nese hack­ers of tar­get­ing US biotechs in a cy­bertheft cam­paign aimed at steal­ing Covid-19 R&D se­crets

3 years ago
China
Coronavirus

GV's David Schenkein comes in to help men­tor — and bankroll — a gene ther­a­py 2.0 play­er, in­trigued by their ‘sci­ence heavy’ ap­proach to con­quer­ing se­vere dis­ease

3 years ago
Financing
Cell/Gene Tx

GSK, Ger­many push coro­n­avirus-fo­cused mR­NA play­er Cure­Vac's lat­est round to $640M

3 years ago
Financing
Coronavirus

No­var­tis qui­et­ly buries an­oth­er failed eczema drug, with a $485M hit em­bed­ded in the foot­notes

3 years ago
R&D

Roche part­ners on a slate of Jnana's im­munol­o­gy, neu­rol­o­gy tar­gets, re­ward­ing its faith in the SLC trans­porter class

3 years ago
Deals

Aca­dia’s shot at beat­ing a ‘fick­le’ ma­jor de­pres­sion chal­lenge miss­es the mark in a failed PhI­II

3 years ago
R&D
FDA+

Not just As­traZeneca — CanSi­no Bi­o­log­ics al­so un­veils Phase II da­ta, show­ing an­ti­body and T cell re­sponse

3 years ago
R&D
Coronavirus

As­traZeneca, Ox­ford re­searchers cham­pi­on a one-two punch against Covid-19 in first hu­man study

3 years ago
R&D
Coronavirus

Ex-Sanofi Gen­zyme chief David Meek­er hops to a new biotech CEO post, this time fo­cus­ing on quick leap to com­mer­cial­iza­tion

3 years ago
People
R&D

Covid-19 roundup: Fau­ci push­es back on Mer­ck’s Fra­zier; Pfiz­er un­veils first vac­cine sup­ply deal as UK nabs 90M more dos­es

3 years ago
Coronavirus
First page Previous page 151152153154155156157 Next page Last page